Hexarelin Technical Overview

Hexarelin, also known as Examorelin or EP-23905, is a synthetic hexapeptide belonging to the growth hormone secretagogue family. It is structurally related to GHRP-6 but contains a modified D-tryptophan residue at the second position.

The peptide interacts with the growth hormone secretagogue receptor (GHS-R1a), a G protein-coupled receptor involved in endocrine signaling and growth hormone secretion. Unlike growth hormone-releasing hormone (GHRH), Hexarelin activates the ghrelin receptor signaling pathway.

Hexarelin is also distinguished by its interaction with CD36, a multifunctional scavenger receptor expressed in several tissues, including cardiac muscle and vascular endothelial cells.

This dual receptor activity has made Hexarelin a subject of experimental investigations into endocrine regulation, cardiovascular signaling, and cellular lipid metabolism.

Published studies have examined its effects on growth hormone secretion, cardiac receptor signaling, myocardial responses, and cholesterol transport mechanisms.

Hexarelin is a synthetic research compound characterized by a linear, C-terminal amidated peptide structure containing six amino acid residues. PubChem

Compound Information

Chemical data: PubChem — Examorelin (CID 6918297)

Specifications refer to the parent Hexarelin peptide. The molecular formula and molecular weight of a particular salt preparation may differ depending on its counterion composition.

Storage and Handling

• Store the compound according to the manufacturer’s recommended temperature and stability conditions.
• Keep the container tightly sealed and protected from light and moisture.
• Avoid unnecessary temperature fluctuations during laboratory storage.
• Minimize repeated freeze-thaw cycles when handling prepared research solutions.
• Follow established laboratory handling procedures to maintain compound integrity.

Lyophilized Format

Hexarelin is commonly supplied for laboratory research in lyophilized (freeze-dried) form.

Lyophilization removes water from peptide preparations and can support chemical stability during storage under appropriate conditions.

The stability of lyophilized Hexarelin depends on its formulation, packaging, moisture exposure, and storage temperature.

Researchers should refer to batch-specific technical documentation for recommended storage conditions.

Research Use Disclaimer

Hexarelin is supplied exclusively for laboratory research purposes.

It is not intended for human or veterinary consumption, clinical use, diagnostic applications, or therapeutic administration.

Hexarelin is not an FDA-approved drug or dietary supplement.

Peptide Lives supplies this compound solely for legitimate scientific research.

HEXARELIN RESEARCH

Hexarelin has been investigated as a synthetic growth hormone secretagogue with activity involving the GHS-R1a receptor.

Early endocrine research established its ability to stimulate growth hormone secretion through pathways distinct from those activated by growth hormone-releasing hormone.

Subsequent investigations identified additional receptor interactions, particularly with CD36, a scavenger receptor associated with lipid transport and cardiovascular signaling.

A 2002 study identified CD36 as a cardiac binding protein for Hexarelin and demonstrated CD36-dependent changes in coronary perfusion pressure in experimental heart models.

Additional research has examined Hexarelin-associated signaling in macrophages, including pathways involved in cholesterol transport and the regulation of lipid metabolism.

These findings have established two principal areas of investigation: growth hormone secretagogue signaling and CD36-associated cardiovascular and metabolic pathways. PubMed

Growth Hormone Secretagogue Signaling

Hexarelin is studied as an agonist of the growth hormone secretagogue receptor (GHS-R1a).

This receptor is involved in the regulation of growth hormone secretion and is also activated by the endogenous peptide hormone ghrelin.

Experimental and clinical pharmacology studies have investigated Hexarelin-associated growth hormone responses and interactions with hypothalamic-pituitary signaling pathways.

Researchers have also examined its influence on other endocrine responses, including cortisol secretion.

These investigations provide information about receptor-mediated hormone regulation and the pharmacological characteristics of synthetic growth hormone secretagogues.

CD36 Binding and Cardiovascular Signaling

One of the distinguishing characteristics of Hexarelin is its interaction with the CD36 scavenger receptor.

CD36 is expressed in several tissues and participates in processes involving fatty acid transport, lipid recognition, and cellular signaling.

A study published in 2002 demonstrated that Hexarelin binds to cardiac CD36 and produces receptor-dependent changes in coronary perfusion pressure in isolated heart preparations.

Subsequent investigations have examined Hexarelin-associated cardiovascular responses in experimental models and small human studies.

These findings have contributed to research into CD36-mediated signaling and the relationship between growth hormone secretagogues and cardiac physiology. PubMed

Myocardial Research

Hexarelin has been studied in experimental models investigating myocardial function and responses to ischemic stress.

In a 2017 rat study, researchers examined Hexarelin-associated changes in cardiac function and interleukin-1 signaling following experimentally induced ischemia-reperfusion injury.

The study reported changes in inflammatory signaling proteins, oxidative stress markers, and cardiomyocyte survival.

These findings concern experimental animal models and do not establish cardiovascular safety or therapeutic effectiveness in humans. PubMed

Lipid Metabolism Research

Hexarelin has also been investigated in cellular models involving cholesterol transport and macrophage signaling.

A 2006 study examined the compound’s interaction with CD36 and GHS-R1a in relation to peroxisome proliferator-activated receptor gamma (PPARγ) signaling.

Researchers reported changes in ATP-binding cassette transporters ABCA1 and ABCG1 and increased cholesterol efflux in experimental macrophage models.

These investigations contribute to understanding the relationship between scavenger receptor activity, nuclear receptor signaling, and cellular lipid transport. PubMed

FREQUENTLY ASKED QUESTIONS

What Is Hexarelin 2mg?

Hexarelin 2mg is a synthetic research hexapeptide also known as Examorelin. It belongs to the growth hormone secretagogue family and is investigated for its interactions with GHS-R1a and CD36 receptors.

What Is the Amino Acid Sequence of Hexarelin?

The amino acid sequence is:

His-D-Trp(2-Me)-Ala-Trp-D-Phe-Lys-NH₂

The peptide contains six amino acid residues, including a 2-methyl-D-tryptophan residue and a C-terminal amide group.

What Are the CAS Number and Molecular Weight of Hexarelin?

Hexarelin has CAS number 140703-51-1 and a molecular weight of approximately 887.0 g/mol.

Its molecular formula is C₄₇H₅₈N₁₂O₆.

These specifications refer to the parent peptide rather than an unspecified salt form.

How Should Hexarelin Be Stored?

Hexarelin should be stored according to the manufacturer’s recommended stability conditions.

The material should remain protected from moisture, direct light, and unnecessary temperature fluctuations.

Storage requirements should be confirmed using the technical documentation for the specific preparation.

What Research Areas Involve Hexarelin?

Hexarelin has been investigated in research involving growth hormone secretagogue signaling, GHS-R1a receptor activation, CD36 binding, myocardial signaling, and cellular cholesterol transport.

What Is the Difference Between Hexarelin and GHRP-6?

Hexarelin and GHRP-6 are structurally related synthetic hexapeptides.

Hexarelin differs from GHRP-6 by the presence of a 2-methyl group on its second amino acid residue, D-tryptophan.

Both compounds interact with the growth hormone secretagogue receptor, while Hexarelin has additionally been characterized in studies examining CD36-associated signaling.

Is Hexarelin Approved for Human Use?

No. Hexarelin is not FDA-approved for human therapeutic use.

Peptide Lives supplies Hexarelin exclusively for laboratory research purposes.

SCIENTIFIC REFERENCES

1. Bodart V. et al. (2002)

CD36 Mediates the Cardiovascular Action of Growth Hormone-Releasing Peptides in the Heart.

Circulation Research.

This study identified CD36 as a cardiac binding protein involved in Hexarelin-associated cardiovascular signaling.

https://pubmed.ncbi.nlm.nih.gov/11988484/

2. Bodart V. et al. (2004)

Identification of the Growth Hormone-Releasing Peptide Binding Site in CD36: A Photoaffinity Cross-Linking Study.

Biochemical Journal.

This research investigated the molecular binding site of Hexarelin on the CD36 receptor.

https://pubmed.ncbi.nlm.nih.gov/15176951/

3. Acute Cardiovascular and Hormonal Effects of GH and Hexarelin, a Synthetic GH-Releasing Peptide, in Humans (1999)

This small human study investigated acute hormonal responses and cardiac function following Hexarelin administration.

https://pubmed.ncbi.nlm.nih.gov/10342360/

4. Effects of Acute Hexarelin Administration on Cardiac Performance in Patients with Coronary Artery Disease During By-Pass Surgery (2002)

This clinical investigation examined short-term cardiovascular responses to Hexarelin in patients undergoing coronary artery bypass surgery.

https://pubmed.ncbi.nlm.nih.gov/12144941/

5. The Growth Hormone Secretagogue Hexarelin Protects Rat Cardiomyocytes From In Vivo Ischemia/Reperfusion Injury Through Interleukin-1 Signaling Pathway (2017)

This experimental study examined myocardial signaling, inflammatory pathways, and cardiac responses in rats.

https://pubmed.ncbi.nlm.nih.gov/28321024/

6. A Growth Hormone-Releasing Peptide That Binds Scavenger Receptor CD36 and Ghrelin Receptor Up-Regulates Sterol Transporters and Cholesterol Efflux in Macrophages Through a Peroxisome Proliferator-Activated Receptor Gamma-Dependent Pathway (2006)

This study investigated Hexarelin-associated CD36 signaling, PPARγ activity, and cholesterol efflux in macrophage models.

https://pubmed.ncbi.nlm.nih.gov/16959872/

CERTIFICATE OF ANALYSIS (COA)

A Certificate of Analysis (COA) provides laboratory testing information about a research compound, including its identity, purity, and other measured characteristics.

Depending on the analytical procedures performed, batch-specific documentation may include results from high-performance liquid chromatography (HPLC) and mass spectrometry (MS).

Researchers should review available analytical documentation to verify compound identity and determine whether the material meets their experimental requirements.

For information about available Hexarelin analytical documentation, contact:

Peptide Lives
Website: https://peptidelives.com